It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Objective
Assessing whether serum Vascular Cell Adhesion Molecule 1(VCAM-1) concentration in the left atrial appendage(LAA) and the expression of VCAM-1 in LAA tissues are associated with the risk of atrial fibrillation-related stroke.
Method
Blood samples were collected from atrial fibrillation(AF) patients scheduled for catheter ablation of AF, both from within the LAA and peripheral veins(PV). The serum concentration of VCAM-1 was quantitatively analyzed using ELISA. Additionally, LAA tissues were obtained from AF patients undergoing cardiac surgery, and immunohistochemical quantification was conducted to assess VCAM-1 expression in these tissues. Univariate analysis and multivariate logistic regression were performed to examine the association between VCAM-1 levels and the risk of atrial fibrillation-related stroke.
Results
A total of 146 patients scheduled for AF ablation and 34 patients scheduled for cardiac surgery were enrolled in this study. Among these two groups, there were 67 cases (45.9%) and 13 cases (38.2%) of AF patients who experienced strokes, respectively. Serum analysis revealed that in the AF group with strokes, the LAA serum VCAM-1 concentration was higher compared to the AF group without strokes (631.64 ± 143.48 pg/ml vs. 336.71 ± 201.66 pg/ml, P < 0.001). Similarly, the PV serum VCAM-1 concentration was higher in the AF group with strokes compared to the group without strokes (591.65 ± 128.23 pg/ml vs. 257.71 ± 157.92 pg/ml, P < 0.001). Additionally, both the AF group with strokes and the group without strokes exhibited higher LAA serum VCAM-1 concentrations compared to PV serum concentrations (631.64 ± 143.48 pg/ml vs. 591.65 ± 128.23 pg/ml, P = 0.041) and (336.71 ± 201.66 pg/ml vs. 257.71 ± 157.92 pg/ml, P = 0.004).Regarding left atrial tissue analysis, the AF group with strokes had a higher average optical density value (AOD) of VCAM-1 compared to the group without strokes (1.257 ± 0.147 vs. 1.093 ± 0.161, P < 0.001), indicating a higher expression level of VCAM-1 in the LAA in the AF group with strokes. In univariate analysis, LAA serum VCAM-1 concentration (OR = 1.15, P < 0.001), PV VCAM-1 concentration (OR = 1.11, P < 0.001), and LAA VCAM-1 AOD value (OR = 3.04, P = 0.021) were all associated with the risk of atrial fibrillation-related stroke. In the multivariate logistic regression analysis, LAA serum VCAM-1 concentration (OR = 1.17, P = 0.002) and PV VCAM-1 concentration (OR = 1.30, P = 0.034) were predictive of atrial fibrillation-related stroke. Specifically, left atrial appendage serum VCAM-1 concentration greater than 387.93 pg/ml and peripheral vein VCAM-1 concentration greater than 344.04 pg/ml were predictive of atrial fibrillation-related strokes.
Conclusions
The risk of stroke in AF is associated with VCAM-1, and elevated serum VCAM-1 concentrations in AF patients who experience strokes may be attributed not only to systemic inflammatory responses but also to increased VCAM-1 expression in LAA tissues. Serum VCAM-1 concentrations in AF patients can serve as predictive factors for atrial fibrillation-related stroke, with LAA serum VCAM-1 concentrations exceeding 387.93 pg/ml and peripheral vein VCAM-1 concentrations exceeding 344.04 pg/ml being predictive of atrial fibrillation-related strokes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer